Used in research and therapeutic development targeting acid-sensing ion channel 1 (ASIC1), this antibody helps modulate neuronal excitability in response to extracellular acidosis. It is applied in studies of neuroinflammation, ischemic brain injury, and multiple sclerosis, where ASIC1 activation contributes to tissue damage. By selectively inhibiting ASIC1, the antibody reduces calcium influx into neurons, thereby protecting against acidosis-induced cell death. It has also been explored in pain pathways, particularly in inflammatory and musculoskeletal pain conditions, due to ASIC1 involvement in nociception. In preclinical models, administration of this antibody demonstrates neuroprotective effects and improved outcomes in stroke and autoimmune encephalomyelitis. Its high specificity makes it a valuable tool for validating ASIC1 as a drug target and for developing biologics in neurological and inflammatory diseases.